Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tranexamic Acid | 3 | 2018 | 121 | 1.95 | Why? |
| Blood Transfusion | 10 | 2020 | 1399 | 1.89 | Why? |
| Blood Donors | 7 | 2021 | 2956 | 1.61 | Why? |
| Hemophilia A | 4 | 2018 | 362 | 1.51 | Why? |
| Factor VIII | 4 | 2018 | 229 | 1.51 | Why? |
| Blood Loss, Surgical | 3 | 2018 | 211 | 1.41 | Why? |
| Fibrinogen | 4 | 2018 | 1048 | 1.39 | Why? |
| Anemia | 5 | 2020 | 789 | 1.35 | Why? |
| Blood Safety | 4 | 2021 | 459 | 1.21 | Why? |
| Blood Preservation | 2 | 2017 | 191 | 1.20 | Why? |
| Erythrocyte Transfusion | 2 | 2017 | 386 | 1.01 | Why? |
| Hemorrhage | 4 | 2018 | 3013 | 0.94 | Why? |
| Coagulants | 2 | 2018 | 30 | 0.88 | Why? |
| Hemostatics | 3 | 2017 | 142 | 0.85 | Why? |
| Tennis Elbow | 1 | 2018 | 6 | 0.77 | Why? |
| Fasciitis, Plantar | 1 | 2018 | 8 | 0.77 | Why? |
| ABO Blood-Group System | 2 | 2018 | 995 | 0.72 | Why? |
| Platelet-Rich Plasma | 1 | 2018 | 91 | 0.70 | Why? |
| Flaviviridae Infections | 1 | 2017 | 27 | 0.67 | Why? |
| Flaviviridae | 1 | 2017 | 60 | 0.66 | Why? |
| Donor Selection | 2 | 2021 | 804 | 0.66 | Why? |
| Iron Chelating Agents | 1 | 2017 | 79 | 0.66 | Why? |
| Platelet Transfusion | 1 | 2018 | 209 | 0.65 | Why? |
| Iron Overload | 1 | 2017 | 113 | 0.61 | Why? |
| Transfusion Medicine | 1 | 2017 | 101 | 0.60 | Why? |
| Thalassemia | 1 | 2017 | 144 | 0.58 | Why? |
| Blood Banks | 2 | 2021 | 535 | 0.57 | Why? |
| Hepatitis E virus | 1 | 2018 | 306 | 0.55 | Why? |
| Chikungunya virus | 1 | 2017 | 339 | 0.54 | Why? |
| Hepatitis E | 1 | 2018 | 319 | 0.52 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.51 | Why? |
| Chikungunya Fever | 1 | 2017 | 345 | 0.50 | Why? |
| Cryopreservation | 1 | 2017 | 464 | 0.50 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2018 | 403 | 0.50 | Why? |
| Thrombelastography | 1 | 2018 | 627 | 0.47 | Why? |
| Hemostasis | 1 | 2018 | 811 | 0.44 | Why? |
| Erythrocytes | 1 | 2017 | 617 | 0.44 | Why? |
| Orthopedic Procedures | 2 | 2018 | 1231 | 0.39 | Why? |
| Immunization, Passive | 4 | 2021 | 10067 | 0.38 | Why? |
| Orthopedics | 2 | 2018 | 1279 | 0.37 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.37 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2018 | 10649 | 0.35 | Why? |
| Blood Coagulation Disorders | 2 | 2020 | 2040 | 0.34 | Why? |
| Cesarean Section | 1 | 2018 | 2089 | 0.34 | Why? |
| Blood Platelets | 1 | 2018 | 1704 | 0.33 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.32 | Why? |
| Disinfection | 1 | 2018 | 2912 | 0.28 | Why? |
| Italy | 9 | 2021 | 38444 | 0.28 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.27 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2018 | 3388 | 0.26 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.26 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.25 | Why? |
| Costs and Cost Analysis | 2 | 2018 | 694 | 0.25 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.23 | Why? |
| Humans | 38 | 2021 | 930598 | 0.20 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.19 | Why? |
| Erythrocyte Aging | 1 | 2017 | 13 | 0.17 | Why? |
| Hepatitis Antibodies | 1 | 2018 | 100 | 0.17 | Why? |
| Antifibrinolytic Agents | 1 | 2018 | 150 | 0.17 | Why? |
| Trauma Severity Indices | 1 | 2017 | 176 | 0.17 | Why? |
| Plasmapheresis | 1 | 2020 | 437 | 0.16 | Why? |
| West Nile virus | 1 | 2018 | 206 | 0.16 | Why? |
| Blood Coagulation Factors | 1 | 2018 | 223 | 0.16 | Why? |
| Culicidae | 1 | 2018 | 239 | 0.16 | Why? |
| West Nile Fever | 1 | 2018 | 166 | 0.16 | Why? |
| PubMed | 1 | 2018 | 246 | 0.15 | Why? |
| Anemia, Iron-Deficiency | 1 | 2017 | 210 | 0.14 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.13 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.13 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.13 | Why? |
| Blood Specimen Collection | 1 | 2017 | 387 | 0.13 | Why? |
| Aorta | 1 | 2016 | 355 | 0.12 | Why? |
| Female | 12 | 2021 | 380317 | 0.12 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.12 | Why? |
| Male | 11 | 2021 | 367725 | 0.12 | Why? |
| von Willebrand Factor | 1 | 2018 | 668 | 0.11 | Why? |
| Blood Coagulation Tests | 1 | 2017 | 855 | 0.11 | Why? |
| Evidence-Based Practice | 1 | 2017 | 693 | 0.11 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.09 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.09 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.09 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.08 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.07 | Why? |
| Adult | 5 | 2021 | 244371 | 0.07 | Why? |
| Disease Management | 2 | 2021 | 6841 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2018 | 2662 | 0.06 | Why? |
| Iron | 2 | 2018 | 619 | 0.06 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.06 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.06 | Why? |
| Operative Blood Salvage | 1 | 2020 | 19 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Aged | 3 | 2021 | 215776 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Middle Aged | 3 | 2021 | 270681 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2021 | 707 | 0.04 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.04 | Why? |
| Syndrome | 1 | 2021 | 1310 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Technology | 1 | 2021 | 812 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| HIV Infections | 1 | 2018 | 11620 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.03 | Why? |
| Animals | 2 | 2018 | 78931 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.03 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.03 | Why? |
| Preoperative Care | 1 | 2020 | 1515 | 0.03 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
Liumbruno's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(140)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(43)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_